ClinicalTrials.gg
CompletedNCT03477175Updated Jan 7, 2025Results posted

Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Participants in Eisai Sponsored Lenvatinib Trials

A Phase 2 interventional study of E7080 and Comparator Drug in Solid Tumors, sponsored by Eisai Inc.. Completed at 28 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-07.

Sponsored by Eisai Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study will be conducted to assess the long-term safety of study drug(s) in participants who are enrolled in Eisai-sponsored lenvatinib studies.

Read the detailed description

This is an open-label extension study to roll-over eligible participants from Eisai-sponsored lenvatinib studies. The participants may roll-over no sooner than the primary completion dates in their parent study or after all study data for the primary outcome measure have been collected for the parent study. The parent study is defined as the Eisai-sponsored lenvatinib clinical study in which the participant was receiving lenvatinib either as monotherapy or as combination therapy or was receiving any other comparator therapy. The participant can be enrolled in the current study for the purpose of long-term safety data collection if all the selection criteria for the current study are met. The intention is that the participant will not be without study drug during the transition from the parent study to the rollover study.

02

Conditions studied

  • Solid Tumors

Keywords

  • lenvatinib
  • E7080
03

In context

Lead sponsor

Eisai Inc. is the lead sponsor of 368 studies on the registry; 7 are open to participants now.

Of its 83 completed or terminated interventional studies of FDA-regulated products, 56 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

It is required for all participants currently participating in other lenvatinib studies to meet the following eligibility criteria.

  • Provide signed written for the roll-over study
  • Currently enrolled in an Eisai-sponsored lenvatinib clinical study and still receiving at least one of the study drugs from that protocol
  • Currently deriving clinical benefit from at least one of the study drug(s) as determined by the investigator
  • Must be able and willing to comply with the current roll-over protocol requirements
  • Continued ability to swallow and retain orally administered study drug(s)
  • Does not have any gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels
  • Women of and men with (if specified by the parent study) must be willing to continue to use highly effective methods of as per local practices of standard of care during the period of the study
  • Women of childbearing potential must have a negative serum pregnancy test at the time of transition to the study and before continuing study drug(s)

Exclusion criteria

Exclusion Criteria:

  • Permanent discontinuation of all study drug(s) in the parent study due to toxicity or disease progression and without clinical benefit
  • Receiving any prohibited medication(s) as described in the parent study
  • Any unresolved toxicity that meets the criteria for study drug(s) discontinuation or withdrawal criteria from the parent study at the time of transition to this study
  • Uncontrolled diabetes, hypertension or other medical conditions at the time of transition to the roll-over study that may interfere with assessment of toxicity
  • Pregnant or lactating female
  • Any serious and/or unstable pre-existing medical condition, psychiatric disorder or other conditions at the time of transition to the roll-over study that could interfere with participant's safety in the opinion of the investigator
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Cohort A : Lenvatinib

    The roll-over eligible participants from Eisai-sponsored lenvatinib studies who received lenvatinib monotherapy or who crossed over from a comparator arm to receive lenvatinib monotherapy in their parent study will continue to receive lenvatinib monotherapy.

    Drug: E7080

  • Experimental
    Cohort B: Lenvatinib plus Comparator drug

    The roll-over eligible participants from Eisai-sponsored lenvatinib studies who received lenvatinib combination therapy or who crossed over from a comparator arm to receive lenvatinib combination therapy in their parent study will continue to receive lenvatinib combination therapy.

    Drug: E7080 · Drug: Comparator Drug

  • Experimental
    Cohort C: Comparator drug

    The roll-over eligible participants from Eisai-sponsored lenvatinib studies who received comparator treatment in their parent study will continue to receive comparator treatment, with exception of participants receiving placebo. For China only: The roll-over eligible participants from Eisai-sponsored lenvatinib studies who received comparator treatment in their parent study will continue to receive sorafenib, with exception of participants receiving placebo.

    Drug: Comparator Drug · Drug: Comparator Drug: Sorafenib

Interventions

  • DrugE7080

    Oral Administration.

    Also known as: lenvatinib, lenvatinib mesilate, lenvatinib mesylate, 4-[3-Chloro-4-(N'-cyclopropylureido)phenoxy]-7-methoxyquinoline-6-carboxamide methanesulfonate

  • DrugComparator Drug

    Per parent study.

  • Per parent study.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Any Treatment-Emergent Serious Adverse Events (TESAEs)

    A treatment-emergent adverse events (TEAE) was defined as an adverse event (AE) that emerged during the treatment in the current roll-over study, having been absent prior to the time the participant signed the current roll-over study informed consent form (ICF), or re-emerged during treatment in the current roll-over study after having been present but resolved before signing the ICF or worsened in severity during treatment in the current roll-over study relative to the pre-ICF state, when the AE was continuous. A serious adverse event (SAE) was any untoward medical occurrence that at any dose: resulted in death; life threatening condition; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect or was medically important due to other reasons than the mentioned criteria.

    Time frame: Up to 58.8 months in current study

  2. Number of Participants With Any Non-Serious Treatment-Emergent Adverse Events (TEAEs)

    A TEAE was defined as an AE that emerged during the treatment in the current roll-over study, having been absent prior to the time the participant signed the current roll-over study in ICF, or re-emerged during treatment in the current roll-over study after having been present but resolved before signing the ICF or worsened in severity during treatment in the current roll-over study relative to the pre-ICF state, when the AE was continuous. A non-serious TEAE was any AE that was not considered a serious adverse event.

    Time frame: Up to 58.8 months in current study

  3. Number of Participants With Treatment-Related TEAEs

    A TEAE was defined as an AE that emerged during the treatment in the current roll-over study, having been absent prior to the time the participant signed the current roll-over study ICF, or re-emerged during treatment in the current roll-over study after having been present but resolved before signing the ICF or worsened in severity during treatment in the current roll-over study relative to the pre-ICF state, when the AE was continuous. Related TEAE was defined as AE with causal relationship between the study drug and the TEAE.

    Time frame: Up to 58.8 months in current study

  4. Number of Participants With Any TEAE

    A TEAE was defined as an AE that emerged during the treatment in the current roll-over study, having been absent prior to the time the participant signed the current roll-over study ICF, or re-emerged during treatment in the current roll-over study after having been present but resolved before signing the ICF or worsened in severity during treatment in the current roll-over study relative to the pre-ICF state, when the AE was continuous.

    Time frame: Up to 58.8 months in current study

07

Results

Posted Jan 7, 2025

Participant flow

Participants took part in the study at 28 investigative sites in China, United States, Australia, Belgium, Germany, Italy, South Korea, Netherlands, Poland, Romania, and Thailand from 16 August 2018 to 21 December 2023.

Participant flow — Overall Study
MilestoneCohort A, China: Lenvatinib MonotherapyCohort A, Rest of the World: Lenvatinib Monotherapy
Started1921
Completed00
Not completed1921
Withdrew: Unable to travel due to covid-1901
Withdrew: Physician decision10
Withdrew: Transitioned to commercial drug66
Withdrew: Lost to follow-up11
Withdrew: Withdrawal by subject31
Withdrew: Adverse event15
Withdrew: Disease progression77

Outcome measures

PrimaryNumber of Participants With Any Treatment-Emergent Serious Adverse Events (TESAEs)

A treatment-emergent adverse events (TEAE) was defined as an adverse event (AE) that emerged during the treatment in the current roll-over study, having been absent prior to the time the participant signed the current roll-over study informed consent form (ICF), or re-emerged during treatment in the current roll-over study after having been present but resolved before signing the ICF or worsened in severity during treatment in the current roll-over study relative to the pre-ICF state, when the AE was continuous. A serious adverse event (SAE) was any untoward medical occurrence that at any dose: resulted in death; life threatening condition; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect or was medically important due to other reasons than the mentioned criteria.

Time frame:
Up to 58.8 months in current study
Reported as:
Count of participants · Participants
Number of Participants With Any Treatment-Emergent Serious Adverse Events (TESAEs)
ParticipantsCohort A, China: Lenvatinib MonotherapyCohort A, Rest of the World: Lenvatinib Monotherapy
Number of Participants With Any Treatment-Emergent Serious Adverse Events (TESAEs)714
PrimaryNumber of Participants With Any Non-Serious Treatment-Emergent Adverse Events (TEAEs)

A TEAE was defined as an AE that emerged during the treatment in the current roll-over study, having been absent prior to the time the participant signed the current roll-over study in ICF, or re-emerged during treatment in the current roll-over study after having been present but resolved before signing the ICF or worsened in severity during treatment in the current roll-over study relative to the pre-ICF state, when the AE was continuous. A non-serious TEAE was any AE that was not considered a serious adverse event.

Time frame:
Up to 58.8 months in current study
Reported as:
Count of participants · Participants
Number of Participants With Any Non-Serious Treatment-Emergent Adverse Events (TEAEs)
ParticipantsCohort A, China: Lenvatinib MonotherapyCohort A, Rest of the World: Lenvatinib Monotherapy
Number of Participants With Any Non-Serious Treatment-Emergent Adverse Events (TEAEs)1817
PrimaryNumber of Participants With Treatment-Related TEAEs

A TEAE was defined as an AE that emerged during the treatment in the current roll-over study, having been absent prior to the time the participant signed the current roll-over study ICF, or re-emerged during treatment in the current roll-over study after having been present but resolved before signing the ICF or worsened in severity during treatment in the current roll-over study relative to the pre-ICF state, when the AE was continuous. Related TEAE was defined as AE with causal relationship between the study drug and the TEAE.

Time frame:
Up to 58.8 months in current study
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Related TEAEs
ParticipantsCohort A, China: Lenvatinib MonotherapyCohort A, Rest of the World: Lenvatinib Monotherapy
Number of Participants With Treatment-Related TEAEs1514
PrimaryNumber of Participants With Any TEAE

A TEAE was defined as an AE that emerged during the treatment in the current roll-over study, having been absent prior to the time the participant signed the current roll-over study ICF, or re-emerged during treatment in the current roll-over study after having been present but resolved before signing the ICF or worsened in severity during treatment in the current roll-over study relative to the pre-ICF state, when the AE was continuous.

Time frame:
Up to 58.8 months in current study
Reported as:
Count of participants · Participants
Number of Participants With Any TEAE
ParticipantsCohort A, China: Lenvatinib MonotherapyCohort A, Rest of the World: Lenvatinib Monotherapy
Number of Participants With Any TEAE1820

Adverse events

Collected over Up to 58.8 months in current study. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort A, China: Lenvatinib Monotherapy2/19 (10.5%)7/19 (36.8%)18/19 (94.7%)
Cohort A, Rest of the World: Lenvatinib Monotherapy5/21 (23.8%)14/21 (66.7%)17/21 (81%)
Most frequent serious events
Showing 10 of 34
Most frequent serious events
EventCohort A, China: Lenvatinib MonotherapyCohort A, Rest of the World: Lenvatinib Monotherapy
PneumoniaInfections and infestations1/192/21
Urinary tract infectionInfections and infestations0/192/21
Large intestine polypGastrointestinal disorders1/190/21
COVID-19Infections and infestations1/191/21
Spinal compression fractureInjury, poisoning and procedural complications1/190/21
Bone painMusculoskeletal and connective tissue disorders1/190/21
Pain in extremityMusculoskeletal and connective tissue disorders1/190/21
Metastases to lungNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/190/21
HypoaesthesiaNervous system disorders1/190/21
SeizureNervous system disorders1/190/21
Most frequent other events
Showing 10 of 79
Most frequent other events
EventCohort A, China: Lenvatinib MonotherapyCohort A, Rest of the World: Lenvatinib Monotherapy
ProteinuriaRenal and urinary disorders6/191/21
Weight decreasedInvestigations0/195/21
COVID-19Infections and infestations4/190/21
Alanine aminotransferase increasedInvestigations4/191/21
Aspartate aminotransferase increasedInvestigations4/191/21
AlbuminuriaRenal and urinary disorders4/190/21
DiarrhoeaGastrointestinal disorders3/194/21
CoughRespiratory, thoracic and mediastinal disorders0/194/21
HypercholesterolaemiaMetabolism and nutrition disorders3/190/21
HypertriglyceridaemiaMetabolism and nutrition disorders3/190/21

Baseline characteristics

Safety analysis set included the group of participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Cohort A, China: Lenvatinib MonotherapyCohort A, Rest of the World: Lenvatinib MonotherapyTotal
Mean56.2 ± 8.1762.7 ± 11.4559.6 ± 10.42
Sex: Female, Male
Sex: Female, Male(Participants)Cohort A, China: Lenvatinib MonotherapyCohort A, Rest of the World: Lenvatinib MonotherapyTotal
Female91221
Male10919
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort A, China: Lenvatinib MonotherapyCohort A, Rest of the World: Lenvatinib MonotherapyTotal
Hispanic or Latino000
Not Hispanic or Latino192140
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort A, China: Lenvatinib MonotherapyCohort A, Rest of the World: Lenvatinib MonotherapyTotal
American Indian or Alaska Native000
Asian19423
Native Hawaiian or Other Pacific Islander000
Black or African American000
White01717
More than one race000
Unknown or Not Reported000
08

Study locations

28 sites
  • Harbor UCLA Medical Center
    Torrance, California 90502, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • The Alfred Hospital
    Melbourne, 3004, Australia
  • UZ Antwerpen
    Edegem, Antwerpen 2650, Belgium
  • Cliniques Universitaires Saint-Luc
    Bruxelles, Brussels 1200, Belgium
  • Sun Yat-sen University, Cancer Center
    Guangzhou, Guangdong, China
  • Affiliated Hospital of Guilin Medical University
    Guilin, Guangxi, China
  • Harbin Medical University Cancer Hospital
    Haerbin, Heilongjiang, China
  • Henan Cancer Hospital
    Zhengzhou, Henan, China
  • Union Hospital Tongji Medical College Huazhong University of Science and Technology
    Wuhan, Hubei, China
  • Hunan Cancer Hospital
    Changsha, Hunan, China
  • Jiangsu Cancer Hospital
    Nanjing, Jiangsu, China
  • Nanjing First Hospital
    Nanjing, Jiangsu, China
  • The First Hospital of Jilin University
    Changchun, Jilin, China
  • No.10 People of Shanghai
    Shanghai, Shanghai, China
  • West China School of Medicine/West China Hospital, Sichuan University
    Chengdu, Sichuan, China
  • Tianjin Medical University Cancer Institute & Hospital
    Tianjin, Tianjin, China
  • Zhejiang Cancer Hospital
    Hangzhou, Zhejiang, China
  • Eisai trial site 2
    Essen, 45147, Germany
  • Eisai trial site 1
    Würzburg, 97080, Germany
  • Azienda Ospedaliero Universitaria Pisana
    Pisa, Toscana 56124, Italy
  • National Cancer Center
    Goyang-si, Gyeonggido 10408, Korea, Republic of
  • Samsung Medical Center - PPDS
    Seoul, 6351, Korea, Republic of
  • Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis
    Amsterdam, Noord-Holland 1066 CX, Netherlands
  • Centrum Onkologii Instytut im.Marii Sklodowskiej Curie-Oddzial w Gliwicach
    Gliwice, 44-101, Poland
  • Institutul National de Endocrinologie "C. I. Parhon"
    Bucharest, 11863, Romania
  • Chulalongkorn University
    Pathum Wan, Krung Thep Maha Nakhon 10330, Thailand
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2018 to primary completion in Dec 2023, 64 months.

Results were first posted in Jan 2025, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2018
First posted
Mar 26, 2018
StartActual
Aug 16, 2018
Primary completionActual
Dec 21, 2023
CompletionActual
Dec 21, 2023
Results first posted
Jan 7, 2025
Last update
Jan 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03477175
Lead sponsor
Eisai Inc.
Responsible party
Sponsor
First posted
Mar 26, 2018
Start date
Aug 16, 2018
Primary completion
Dec 21, 2023
Completion
Dec 21, 2023
Results posted
Jan 7, 2025
Last update
Jan 7, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lenvatinib · Sorafenib

Start the discussion